Paper39587494
Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.
Yu C and 7 others. BMC Cancer, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes. Papers, record 39587494. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39587494
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Immunoglobulin Light-chain Amyloidosis | Major topic |
| Chromosome Aberrations | Major topic |
| Humans | |
| Female | |
| Male | |
| Aged | |
| Middle Aged | |
| Retrospective Studies | |
| Prognosis | |
| Aged, 80 and over | |
| Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 22ZR1411400 | Natural Science Foundation of Shanghai | PubMed |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23541011 | Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. | Mayo Clin Proc | 2013 | https://conductscience.org/library/papers/23541011 | PubMed |
| 2 | 30104177 | Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. | Clin Lymphoma Myeloma Leuk | 2018 | https://conductscience.org/library/papers/30104177 | PubMed |
| 3 | 37968258 | Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies. | Blood Cancer J | 2023 | https://conductscience.org/library/papers/37968258 | PubMed |
| 4 | 23091105 | New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/23091105 | PubMed |
| 5 | 27257181 | Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. | Blood | 2016 | https://conductscience.org/library/papers/27257181 | PubMed |
| 6 | 35429180 | Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment. | Am J Hematol | 2022 | https://conductscience.org/library/papers/35429180 | PubMed |
| 7 | 23432783 | The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. | Br J Haematol | 2013 | https://conductscience.org/library/papers/23432783 | PubMed |
| 8 | 36779691 | Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. | Amyloid | 2023 | https://conductscience.org/library/papers/36779691 | PubMed |
| 9 | 36652935 | Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2023 | https://conductscience.org/library/papers/36652935 | PubMed |
| 10 | 23456262 | Molecular pathogenesis of multiple myeloma: basic and clinical updates. | Int J Hematol | 2013 | https://conductscience.org/library/papers/23456262 | PubMed |
| 11 | 33594045 | Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. | Blood Cancer J | 2021 | https://conductscience.org/library/papers/33594045 | PubMed |
| 12 | 26240224 | Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26240224 | PubMed |
| 13 | 30327369 | Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. | Blood Adv | 2018 | https://conductscience.org/library/papers/30327369 | PubMed |
| 14 | 29482381 | Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome. | Amyloid | 2018 | https://conductscience.org/library/papers/29482381 | PubMed |
| 15 | 12393530 | Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. | Blood | 2003 | https://conductscience.org/library/papers/12393530 | PubMed |
| 16 | 20194151 | Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma. | Mayo Clin Proc | 2010 | https://conductscience.org/library/papers/20194151 | PubMed |
| 17 | 32010993 | Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. | Am J Hematol | 2020 | https://conductscience.org/library/papers/32010993 | PubMed |
| 18 | 34517412 | How I treat AL amyloidosis. | Blood | 2022 | https://conductscience.org/library/papers/34517412 | PubMed |
| 19 | 25439696 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/25439696 | PubMed |
| 20 | 16715110 | Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? | Bone Marrow Transplant | 2006 | https://conductscience.org/library/papers/16715110 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42807240 | Periorbital hyperpigmentation as the initial manifestation of smoldering multiple myeloma in a patient with coexisting gastrointestinal stromal tumor: a case report and narrative literature review. | Front Oncol | 2026 | https://conductscience.org/library/papers/42807240 | PubMed |
| 42278643 | Multiple Myeloma Concomitant with AL Amyloidosis: Histopathological Aspects of the Common Plasma Cell Spectrum. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42278643 | PubMed |
| 41452481 | Bortezomib combined with autologous stem cell transplantation overcomes cytogenetic abnormalities in AL amyloidosis. | Int J Hematol | 2026 | https://conductscience.org/library/papers/41452481 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39587494
GET https://conductscience.org/api/papers/v1/39587494/references?page=2